MBX Biosciences (MBX) Liabilities and Shareholders Equity (2023 - 2026)

MBX Biosciences (MBX) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $452.7 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 84.08% year-over-year to $452.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (up 84.4% YoY), and the FY2025 full-year result was $385.1 million, up 43.42% from the prior year.
• Liabilities and Shareholders Equity advanced to $452.7 million in Q1 2026, from $385.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $452.7 million in Q1 2026 to a low of $84.2 million in Q4 2023.
• A 4-year average of $293.8 million and a median of $275.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity surged 219.0% in 2024 and jumped 41.67% in 2025, its largest moves.
• Tracing MBX's Liabilities and Shareholders Equity over 4 years: stood at $84.2 million in 2023, then surged by 219.0% to $268.5 million in 2024, then soared by 43.42% to $385.1 million in 2025, then climbed by 17.54% to $452.7 million in 2026.
• Business Quant data shows MBX's Liabilities and Shareholders Equity at $452.7 million in Q1 2026, $385.1 million in Q4 2025, and $400.1 million in Q3 2025.